Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | FDPS | P14324 | 2/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.30 |
| ▸ | CDC25B | P30305 | 1/20 | 0.30 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.30 |
| ▸ | GGPS1 | O95749 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8810608 | 1.00 | LMNA (0.52) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL8812633 | 1.00 | LMNA (0.52) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL27735903 | 1.00 | LMNA (0.52) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL3035339 | 0.92 | LMNA (0.52) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL8811039 | 0.92 | LMNA (0.52) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL16174549 | 0.88 | LMNA (0.54) | LMNABLMPTPN1ALOX15MEN1 | |
| SCHEMBL3034457 | 0.87 | ALDH1A1 (0.33) | LMNAALOX15ALDH1A1 | |
| SCHEMBL21518273 | 0.87 | ALOX15 (0.36) | ALOX15 | |
| SCHEMBL3043256 | 0.83 | TSHR (0.39) | LMNAALOX15CYP3A4FDPSALDH1A1 | |
| SCHEMBL93213 | 0.82 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 503 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260096991-A1 | BIODEGRADABLE MICROCAPSULES AND METHOD FOR THEIR PREPARATION | XAMPLA LTD (GB) | 2026-04-09 | — | — | US | disclosed |
| EP-4489592-B1 | BIODEGRADABLE MICROCAPSULES AND A METHOD FOR THEIR PREPARATION | XAMPLA LTD (GB) | 2025-12-24 | — | — | EP | disclosed |
| US-20250255827-A1 | BIODEGRADABLE MICROCAPSULES AND A METHOD FOR THEIR PREPARATION | XAMPLA LIMITED (GB) | 2025-08-14 | — | — | US | disclosed |
| EP-4593639-A1 | BIODEGRADABLE MICROCAPSULES AND METHOD FOR THEIR PREPARATION | Xampla Limited (GB) | 2025-08-06 | — | — | EP | disclosed |
| US-20250186960-A1 | BIODEGRADABLE MICROCAPSULES AND A METHOD FOR THEIR PREPARATION | XAMPLA LIMITED (GB) | 2025-06-12 | — | — | US | disclosed |
| EP-3888782-B1 | COATED MICROCAPSULES | NOXELL CORP (US) | 2025-06-11 | — | — | EP | disclosed |
| US-20250177298-A1 | EMULSIONS AND A METHOD FOR THEIR PREPARATION | XAMPLA LIMITED (GB) | 2025-06-05 | — | — | US | disclosed |
| WO-2025109106-A1 | CORE-SHELL MICROCAPSULES | XAMPLA Ltd. (GB) | 2025-05-30 | — | — | WO | disclosed |
| US-20250049660-A1 | ENOL ETHER PROPERFUME | FIRMENICH SA (CH) | 2025-02-13 | — | — | US | disclosed |
| EP-4489900-A1 | BIODEGRADABLE MICROCAPSULES AND METHOD FOR THEIR PREPARATION | Xampla Limited (GB) | 2025-01-15 | — | — | EP | disclosed |
| EP-0462531-B1 | Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain | FUJISAWA PHARMACEUTICAL CO (JP) | 1996-10-02 | — | — | EP | disclosed |
| EP-0729974-A1 | Cyclic polypeptide with antibiotic activity and a process for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-09-04 | — | — | EP | disclosed |
| EP-0536936-B1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | SANKYO CO (JP) | 1996-08-14 | — | — | EP | disclosed |
| WO-1995019959-A1 | AMINO ACID DERIVATIVES AND THEIR USE AS PHOSPHOLIPASE A2 INHIBITORS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-07-27 | — | — | WO | disclosed |
| EP-0644199-A1 | Cyclic antimicrobial peptides and preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1995-03-22 | — | — | EP | disclosed |
| US-5376634-A | Microbiocides | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1994-12-27 | — | — | US | disclosed |
| EP-0536936-A1 | Pyrimidine nucleoside derivatives having anti-tumor activity, their preparation and use | Sankyo Company Limited (JP) | 1993-04-14 | — | — | EP | disclosed |
| EP-0486011-A2 | Pharmaceutical composition against Pneumocystis carinii | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-05-20 | — | — | EP | disclosed |
| EP-0462531-A2 | Cyclic polypeptide with antibiotic activity, process for its preparation and pure culture of a Coelomycetes strain | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-27 | — | — | EP | disclosed |
| US-4791050-A | TWO-LAYER BLUE-SENSITIVE EMULSION CONTAINING DIFFERENT YELLOW COUPLERS; LIGHTFAST IMAGES | FUJI PHOTO FILM CO., LTD. (JP) | 1988-12-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260096991-A1 | BIODEGRADABLE MICROCAPSULES AND METHOD FOR THEIR PREPARATION | PCTP, CLK4, MTCL3 | LMNA 1834/4885BLM 3456/4885PTPN1 3562/4885 |
| US-20250049660-A1 | ENOL ETHER PROPERFUME | CYP2E1, ADH5, ECI1 | LMNA 1640/4885BLM 4579/4885PTPN1 4819/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.